UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 13, 2025

Akari Therapeutics, Plc
(Exact Name of Registrant as Specified in Charter)

England and Wales	**001-36288**	**98-1034922**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

22 Boston Wharf Road FL 7
Boston, MA 02210
(Address, including zip code, of Principal Executive Offices)

Registrant's telephone number, including area code: (929) 274-7510

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	**Trading Symbol(s)**	**Name of each exchange on which registered**
American Depositary Shares, each representing 2,000 Ordinary Shares	AKTX	The Nasdaq Capital Market
Ordinary Shares, par value $0.0001 per share*		

*Trading, but only in connection with the American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 13, 2025, Akari Therapeutics, Plc (the "Company") updated information reflected in a slide presentation, which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings from time to time.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Akari Therapeutics, Plc

Date: January 13, 2025

By: /s/ Samir R. Patel, M.D.

Samir R. Patel, M.D.
President and Chief Executive Officer



Next-Generation Precision Bi-Functional Antibody Drug Conjugates

AKARI THERAPEUTICS

Corporate Presentation
January 2025

NASDAQ: AKTX
akaritx.com

Forward-Looking Statements

This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc (the "Company") that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "future," "opportunity" "will likely result," "target," variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the business combination and related matters, including, but not limited to, post-closing operations and the outlook for the Company's business; the Company's targets, plans, objectives or goals for future operations, including those related to its product candidates; financial projections; future economic performance; and the assumptions underlying or relating to such statements. These statements are based on the Company's current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the risk that the Company may not realize the anticipated benefits of its merger with Peak Bio, Inc. (the "Merger") in the time frame expected, or at all; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from the Merger; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business; uncertainties as to the long-term value of the Company's American Depositary Shares ("ADSs") (and the ordinary shares represented thereby), including the dilution caused by the Company's issuance of additional ADSs (and the ordinary shares represented thereby) in connection with the Merger; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company's programs or product candidates; risks related to any loss of the Company's patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company's product candidates, the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company's product candidates; unexpected breaches or terminations with respect to the Company's material contracts or arrangements; risks related to competition for the Company's product candidates; the Company's ability to successfully develop or commercialize its product candidates; potential exposure to legal proceedings and investigations; risks related to changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing, development or commercialization of any of the Company's product candidates; the Company's ability to maintain listing of its ADSs on the Nasdaq Capital Market. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

AKARI
THERAPEUTICS

WE ARE

AKARI THERAPEUTICS

Akari Therapeutics is an innovative targeted oncology company built on next-generation ADCs and a novel discovery engine

Why Akari

Innovative Precision Antibody Drug Conjugates (ADCs) for the Treatment of Cancer

Discovery platform allows for generation of novel Bi-Functional ADC candidates with spliceosome inhibitor payload

Tunable Target, Linker and Payload

Lead Candidate AKTX-101 (TROP2 PH1 ADC)

Significant advantages over current TROP2 ADCs observed in multiple preclinical models:

- Superior activity
- Prolonged survival
- Less resistance
- Better tolerability
- Prolonged survival in combination with checkpoint inhibitors (CPI)

Capital Efficient with Multiple Near-Term Milestones

- Lean team focused on Execution
- Opportunity for Non-Dilutive Capital Through Partnering of Legacy Pipeline
- BD Discussions ongoing with interested licensing/strategic partners

AKARI THERAPEUTICS

ADCs Have Revolutionized Cancer Therapy, But Have Some Shortcomings

All Currently Approved ADCs Utilize Only One of Two Payload Toxin Classes, Which Are Known for Toxicity and Resistance Issues

Tubulin Inhibitors | DNA Damaging Agents

Limited Combination Ability with Other Key Therapies Like Anti-PD1/Anti-PDL1

AKARI THERAPEUTICS

1. *Antibody drug conjugates market*. Market.us. (2023, November 3). https://market.us/report/antibody-drug-conjugates-market/

2023 Sales from Approved ADCs

	Product	Toxin Class	2023 Sales
Solid Tumors	TRODELVY	DNA Damaging Agent	$1.0B
	ENHERTU	DNA Damaging Agent	$2.7B
	tivdak	Microtubule Inhibitor	<$100M
	Kadcyla	Microtubule Inhibitor	$1.75B
	PADCEV	Microtubule Inhibitor	$1.3B
	ELAHERE	Microtubule Inhibitor	$150M
Liquid Tumors	POLIVY	Microtubule Inhibitor	$750M
	ADCETRIS	Microtubule Inhibitor	$1.5B
	zynlonta	DNA Damaging Agent	<$100M
	BESPONSA	DNA Damaging Agent	$140M
	MYLOTARG	DNA Damaging Agent	<$100M



Bi-Functional ADC Platform Targeting Cancer

Highly Selective Cancer Cell Death Combined With Enhanced Immune System Engagement for Effective Tumor Eradication

Antibody
Targeting Clinically Validated TROP2 Receptor on Tumor Cells

Linker
Connects Anti-Tumor Payload to Targeting Antibody

Payload
Differentiated Novel PH1 Payload Disrupts Normal RNA Splicing, Leading to Cancer Cell Apoptosis

Potential to Overcome Shortcomings of Current ADCs

- ✓ Low Off-Target Toxicity
- ✓ Enhanced Activity as a Single Agent
- ✓ Potential to Overcome Tumor Resistance Mechanisms
- ✓ Ability to Induce Epitope Spreading

AKARI THERAPEUTICS

Next-Generation Precision ADC Pipeline

Program	Indication	Discovery	Preclinical	Clinical	Highlights
AKTX-101 **(TROP2 PH1 ADC)** *ADC with Novel Payload*	**Solid Tumors**				• **Novel Payload: PH1** • Advancing IND-enabling preclinical studies • Pursue licensing / strategic partnership
AKTX-102 **(Undisclosed Target)** *ADC with Novel Payload*	**Undisclosed**				• **Novel Payload: PH5** Payload targeting DNA Mismatch Repair (MMR) to generate neoepitopes
AKTX-103 **(Undisclosed Target)** *ADC with Novel Payload*	**Undisclosed**				• **Novel Payload: PH6** Payload targeting DNA transcription in cancer cells and co-opted immune cells

Platform Technology to Fuel Pipeline with Ability to Generate Novel ADC Candidates Across a Range of Solid/Hematological Cancers

AKARI THERAPEUTICS

Akari Platform Technology Can Fuel a Pipeline

Ability to Precisely Tune Assets for Purpose Allows for Multiple Program Development for Additional Licensing Partnerships



Proprietary to Akari

Program

AKTX-101

Ability to generate novel ADC candidates against any relevant target across a range of cancers

AKARI THERAPEUTICS

Novel PH1 Payload: Superior Activity With Potent Effect Across Various Tumors Types and Targets Using Platform Technology

In Vitro Studies Performed at Lower PH1 Drug Dose (Lower DAR)

Trop2

Gastric Trop^{High}



Bladder Trop2^{Heterogenous}



Pancreatic Trop2^{High}



Her2

Gastric Her2^{High}



Breast Her2^{Low}



Undisclosed

NSCLC Target^{Medium}



AKARI THERAPEUTICS

These data are derived from comparative non-clinical studies and are not intended to serve as a basis for comparison with respect to Trodelvy's or any other clinical studies.

AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms

Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity

Potential to Overcome Shortcomings of Current ADCs

Immunostimulatory Effects

Accumulation of mis-spliced proteins generates neoantigens that can be recognized by the immune system, potentially enhancing anti-tumor immunity

Reduced Off-Target Toxicity

Proprietary linker and tumor selective antibodies that spare normal cells potentially reducing off-target toxicity

Overcomes Resistance Mechanisms

Appears to be a poor substrate for MDR transporters, which are often responsible for drug resistance in cancer therapy

Potential for Synergy With Immunotherapies

Immunomodulatory properties may synergize with checkpoint inhibitors and other immunotherapies

AKARI THERAPEUTICS


AKTX-101: Direct Tumor Cell Cytotoxicity and Generation of Neoantigens
Bi-Functional Payload Targeting the Spliceosome
1
PH1 ADC binds to the target receptor.
PH1
TROP2
TUMOR CELL MEMBRANE
Endosome
2
Antibody receptor complex is internalized by endocytosis.
3
Lysosome fuses with endosome. Lysosomal enzymes degrade the ADC, releasing the active payload species.
Active payload
NUCLEUS
SF3B1
PH5α
SF3B2
4
PH1 disrupts alternative splicing in the tumor cell, a fundamental process for tumor transformation and growth.
Spliceosome
Pre-mRNA
Bi-functional results of PH1 targeted splicing
MHC
Neoantigen
Neoantigen formation can stimulate the immune response and induce tumor growth inhibition (TGI) in syngeneic model.
Ribosome
mRNA
Payload cytotoxicity and TGI in xenograft models
Resulting mRNA decay deprives cancer cells of essential proteins.
Accumulation of mis-spliced proteins induce cell death by unfolded protein response (UPR) and endoplasmic reticulum stress.
11

AKTX-101:
Immune Response to Payload-Induced Neoantigens Extends Beyond ADC Target Receptor



PH1 Payload Treated Mice Retained Immune Memory and Rejected Rechallenge with Tumor Cells

Potent Synergy With Checkpoint Inhibitor Has Potential to Cure Colorectal Tumors

PH1 Induced Tumor-Specific Immune Memory









AKARI THERAPEUTICS

AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms

Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity

Potential to Overcome Shortcomings of Current ADCs

Immunostimulatory Effects

Accumulation of mis-spliced proteins generates neoantigens that can be recognized by the immune system, potentially enhancing anti-tumor immunity

Reduced Off-Target Toxicity

Proprietary linker and tumor selective antibodies that spare normal cells potentially reducing off-target toxicity

Overcomes Resistance Mechanisms

Appears to be a poor substrate for MDR transporters, which are often responsible for drug resistance in cancer therapy

Potential for Synergy With Immunotherapies

Immunomodulatory properties may synergize with checkpoint inhibitors and other immunotherapies

AKARI THERAPEUTICS

AKTX-101: Demonstrated Reduced Off-Target Toxicity in Preclinical Study

Limited effect on Normal Human Fibroblasts, an example of off-target toxicity of Trodelvy®

Proprietary Linker Only Releases PH1 Payload Upon Cell Internalization – No Leakage

Suggests Potential for Higher Therapeutic Index

AKARI THERAPEUTICS

Normal Human Fibroblasts TROP2^{none}



No cytotoxicity against normal human fibroblasts as observed in FIC (Attributed to superior linker stability)

These data are derived from comparative non-clinical studies and are not intended to serve as a basis for comparison with respect to Trodelvy's or any other clinical studies.

AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms

Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity

Potential to Overcome Shortcomings of Current ADCs

Immunostimulatory Effects

Accumulation of mis-spliced proteins generates neoantigens that can be recognized by the immune system, potentially enhancing anti-tumor immunity

Reduced Off-Target Toxicity

Proprietary linker and tumor selective antibodies that spare normal cells potentially reducing off-target toxicity

Overcomes Resistance Mechanisms

Appears to be a poor substrate for MDR transporters, which are often responsible for drug resistance in cancer therapy

Potential for Synergy With Immunotherapies

Immunomodulatory properties may synergize with checkpoint inhibitors and other immunotherapies

AKARI THERAPEUTICS

AKTX-101: Shown to Avoid Development of Resistance in Preclinical Study

PH1 Payload is Designed to Evade MDR Transporter Efflux Pumps and is unaffected by mutations in Tubulin or DNA Damage Pathways that confer resistance to microtubule and topoisomerase inhibitor payloads

Patients who develop resistance to current TROP2 ADCs, may still be candidates for AKTX-101 due to differentiated PH1 payload mechanism

Method: Normal MES-SA cells & MES-SA cells selected for overexpression of MDR transporter 1/2 exposed *in vitro* to PH1 or anti-tubulin payload MMAE (monomethyl auristatin E), in presence or absence of MDR 1/2 inhibitor elacridar

- MES-SA uterine sarcoma cell line
- MES-SA cells expressing high levels of MDR transporter 1 and 2 which can pump toxins out of cells
- MES-SA cells with high MDR expression + MDR inhibitor elacridar

AKARI THERAPEUTICS



PH1 potency unaffected by overexpression of multidrug resistance (MDR) transporters



200X higher MMAE concentration required to kill cells overexpressing MDRs; inhibition of MDR 1/2 by elacridar restores MMAE potency

AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms

Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity

Potential to Overcome Shortcomings of Current ADCs

Immunostimulatory Effects

Accumulation of mis-spliced proteins generates neoantigens that can be recognized by the immune system, potentially enhancing anti-tumor immunity

Reduced Off-Target Toxicity

Proprietary linker and tumor selective antibodies that spare normal cells potentially reducing off-target toxicity

Overcomes Resistance Mechanisms

Appears to be a poor substrate for MDR transporters, which are often responsible for drug resistance in cancer therapy

Potential for Synergy With Immunotherapies

Immunomodulatory properties may synergize with checkpoint inhibitors and other immunotherapies

AKARI THERAPEUTICS

AKTX-101 Demonstrated Anti-Tumor Activity and Improved Overall Survival in Combination With Standard of Care I/O

Mouse Bladder Syngeneic Cancer Tumor Model (Urothelial) Expressing Human TROP2 Protein

Superior Anti-Tumor Efficacy In Combination With IO



Comparable to SOC and Superior in Combination With I/O

Superior Overall Survival Combination With IO



Note: Patent pending so exact model, I/O drug and dosing not disclosed

Benefit in OS Compared to SOC and Superior in Combination With I/O

AKARI THERAPEUTICS

Significant Big Pharma Interest and Deal Flow in Early-Stage ADCs

Licensee	Licensor	Phase	Asset	Target	Date	Deal Type	Upfront Payment	Total Deal Highlights
Synaffix	Boehringer Ingelheim	Preclinical	ADC Technologies	Undisclosed	1/2025	Licensing	**Undisclosed**	Undisclosed upfront payment and up to $1.3 billion, plus additional royalty payments on net sales of resulting products
DualityBio 映恩生物	AVENZO THERAPEUTICS	Preclinical	AVZO-1418/DB-1418	EGFR/HER3	1/2025	Licensing	**$50M**	$50 million and will be eligible to receive up to approximately $1.15 billion in development, regulatory and commercial milestone payments
WuXi Biologics Global Solution Provider	ADI bioscience	Preclinical	3 ADCs	PTK7-ADC, MUC16-ADC, SEZ6-ADC	12/2024	Licensing	**$44M**	$44M upfront + $265M in development and $540M in commercial milestones, plus single-digit royalty (all 3 assets included)
Synaffix	ELEVATION ONCOLOGY	Preclinical	EO-1022	HER3	12/2024	Licensing	**$368M**	$368 million in upfront and clinical, regulatory, and commercial milestone payments, plus tiered royalties on net sales
DualityBio 映恩生物	GSK	Preclinical	DB-1324	Undisclosed	12/2024	Licensing	**$30M**	$30M upfront, plus pre-option milestones and up to $975M in milestones and tiered royalties on sales
TUBULIS	GILEAD	Preclinical	Alco5 Tech	Undisclosed	12/2024	Licensing	**$20M**	$20M upfront, plus potential for $30M option and up to $415M in milestones and low double-digit royalties
VelaVigo	AVENZO THERAPEUTICS	Preclinical	VAC-103	Nectin4/ TROP2	11/2024	Option	**$50M**	$50 million and potential development, regulatory, and commercial milestone payments of up to approximately $750 million in total, as well as tiered royalties on sales
KELUN-BIOTECH 科伦博泰	MERCK	Preclinical	SKB571	Undisclosed	9/2024	Licensing	**$35M**	$35m upfront, $37.5m on option exercise, undisclosed sales milestones and tiered royalties
宜联生物 MediLink Therapeutics	BIONTECH	Preclinical	TMALIN ADC platform	Undisclosed	6/2024	Licensing	**$25M**	$25M upfront; Up to $1.8B in milestones
CARIS LIFE SCIENCES	MERCK	Preclinical	Targets	Undisclosed	4/2024	Licensing	**NA**	Up to $1.4B in milestones
SUTRO BIOPHARMA	IPSEN Innovation for patient care	Preclinical	STRO-003	ROR1	4/2024	Licensing	**$90M**	$90M upfront; Phase 1 by Ipsen $900M in milestones
礼新医药 LaNova Medicines	AstraZeneca	Preclinical	LM-305	GPRC5D	4/2023	Licensing	**$55M**	$55M upfront; $545M milestones
TUBULIS	Bristol Myers Squibb	Preclinical	Tubutecan payloads and p5 conjugation platform	Undisclosed	4/2023	Collaboration	**$22M**	$22.75M upfront; $1B milestones
KELUN-BIOTECH 科伦博泰	MERCK	Preclinical	Undisclosed	Undisclosed	7/2022	Licensing	**$35M**	$35M upfront; $901M milestones
immunogen	Lilly	Preclinical	Camptothecins	Undisclosed	2/2022	Licensing	**$13M+$32.5M**	$13M+$32.5M upfront; $1.7B milestones

Proven Management Team

Samir R. Patel, MD
Chief Executive Officer

Serial entrepreneur with more than 20 years of experience in life sciences with multiple successful exits

REZOLUTE · Johnson & Johnson · centocor · PranaBio INVESTMENTS · dell children's medical center of central texas · AKARI THERAPEUTICS

Torsten Hombeck, PhD
Chief Financial Officer

Seasoned executive with over 20 years of expertise in finance, capital markets and M&A

Cellaïon · ASPIRA WOMEN'S HEALTH · GPC biotech · Beiersdorf · cytonet

Miles Nunn, D. Phil
Chief Scientific Officer

Accomplished scientist and drug developer with over two decades of experience, including the discovery of nomacopan

UK CEH

Satyajit Mitra, PhD
Executive Director, Head of Oncology

Scientist with 20 years in advancing novel oncology programs from early preclinical validation and lead selection through pipeline nomination

pH PHARMA · USC University of Southern California · VasGene Therapeutics Inc.™ · OncoMed PHARMACEUTICALS · Scripps Research

Highly Experienced, Involved, Knowledgeable Board to Help Steer Strategy and Execution

Hoyoung Huh, MD, PhD
Chairman
Founder of Peak Bio Inc. and has held positions of Chief Executive Officer and Board Chairman since founding pH Pharma in 2015

Samir R. Patel, MD
Chief Executive Officer
CEO since December of 2024, founder and principal of PranaBio Investments, has more than 20 years of experience in life sciences including co-founding Digital Therapeutics, LLC

Ray Prudo, MD
Director
Founder, Chairman, and CEO of Volution and its predecessor company, Varleigh Immuno Pharmaceuticals, and is currently a board member of several UK healthcare companies

James Neal, MS, MBA
Director
More than 25 years' experience in forming and maximizing business and technology collaborations globally and in bringing novel products and technologies to market

Sandip I. Patel JD, BBA
Director
Involved in the formation, development, growth, and successful exits of several companies in the healthcare services and technology sector, insurance, and financial services

Robert Bazemore
Director
Seasoned executive leader, board member and innovator with over 35 years experience in portfolio strategy, partnering, development and commercialization of novel therapeutics, predominantly in Oncology and Immunology

Abizer Gaslightwala
Director
25 years in the development and commercialization of novel medicines with extensive experience in Oncology; developed, launched, and driven growth of several oncology products and brands spanning cancers with a focus on targeted agents including HER2, VEGF, CD20, and EGFR

AKARI THERAPEUTICS

Upcoming Expected Value Driving Milestones

Building a Next-Generation Precision Bi-Functional ADC Platform

Ongoing and Near-Term

- Present anticipated PH1 Payload Preclinical Data at Scientific Conference
- Complete additional IND-enabling preclinical studies for AKTX-101
- Generate additional validating data on novel payloads to support pipeline
- Round out Executive Team with critical hires
- Seeking licensing/strategic partner for **AKTX-101** **(TROP2 PH1 ADC)**

Legacy Pipeline Assets

Ongoing

BD Efforts To Secure Development Partners And Provide Non-Dilutive Capital

AKARI THERAPEUTICS

Assets Beyond ADC Platform

Opportunity for Non-Dilutive Capital Through Ongoing BD Activities to Secure Development Partner for Inactive Programs

Program	Indication	Discovery / Preclinical / Phase 1 / Phase 2 / Phase 3	Global Market Opportunity
PAS-Nomacopan *Long-Acting Complement C5 & Leukotriene B4 Inhibitor for Eye*	Geographic Atrophy		$23 Billion[1]
PHP-303 *Neutrophil Elastase Inhibitor*	Alpha-1 Antitrypsin Deficiency		$1.4 Billion[2]
	Acute Respiratory Distress Syndrome		$3.4 Billion[3]
Nomacopan *Complement C5 & Leukotriene B4 Inhibitor for Systemic Conditions*	Bullous Pemphigoid; Paroxysmal Nocturnal Hemoglobinuria		>$5 Billion[4]
	Trauma		$15 Billion[5]

AKARI THERAPEUTICS

1. Geographic atrophy (GA) market size, Share report, 2024-2032. Geographic Atrophy (GA) Market Size, Share Report, 2024-2032. (n.d.). https://www.snsinsider.com/reports/geographic-atrophy-ga-market-2480
2. Alpha-1 antitrypsin deficiency market size & forecast - 2034. Size & Forecast - 2034. (n.d.). https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-market
3. Global acute respiratory distress syndrome (ARDS) treatment market size: Mordor Intelligence. Mordor Intelligence Market Research Company. (n.d.). https://www.mordorintelligence.com/industry-reports/acute-respiratory-distress-syndrome-treatment-market
4. Paroxysmal nocturnal hemoglobinuria treatment market 2030. Paroxysmal Nocturnal Hemoglobinuria Treatment Market 2030. (n.d.). https://www.grandviewresearch.com/industry-analysis/paroxysmal-nocturnal-hemoglobinuria-pnh-market
5. Trauma Care Centers Market Size & Share Report, 2022-2030. (n.d.). https://www.grandviewresearch.com/industry-analysis/trauma-care-centers-market

Why Now

Next-Generation Precision Antibody Drug Conjugates (ADC) Candidates for the Treatment of Cancer

Innovative Bi-Functional ADC Platform Technology

Customizable Targets by Tumor, Novel Payloads, Unique Linkers to Generate a Pipeline of Superior ADCs for Out-Licensing Opportunities

AKTX-101 (TROP2 PH1 ADC)

Next-Generation Precision Bi-Functional ADC With Novel Spliceosome Inhibiting Payload Designed to Overcome Limitations of Current ADCs

Significant Deal-Flow for Early-Stage ADC

Continued Recent Momentum of ADC Deals Underscores Big Pharma Growing Interest and Engagement for Potential Deal

Capital Efficient Strategy
Focused on Execution



Ongoing Robust BD Effort to Secure Licensing/Strategic Partner for AKTX-101 and Potential for Upside From Licensing of Non-Core Assets



Next-Generation Precision Bi-Functional Antibody Drug Conjugates

AKARI THERAPEUTICS

Investor Relations
JTC Team
aktx@jtcir.com
(908) 824-0775